Archive

Filter

AbbVie Pipeline Runneth Over During an R&D Day to update investors on its pipeline development, AbbVie (NYSE: ABBV) said that it has more than 50 active clinical development programs right now and expects at least seven new approvals this year. Based on its late-stage pipeline as it stands now, it expects… Read More